Apoptosis pathway regulatory proteins

Apoptosis pathway regulatory proteins constitute a complex network of signaling molecules that orchestrate programmed cell death, a fundamental biological process essential for development and tissue homeostasis (Youle & Strasser, 2008). This group primarily includes the B-cell lymphoma 2 (Bcl-2) family of proteins, which act as a rheostat for mitochondrial integrity, as well as the caspase family of cysteine proteases and Inhibitor of Apoptosis Proteins (IAPs) (Shalini et al., 2015). Dysregulation of these regulators is a hallmark of various pathologies; for instance, the overexpression of anti-apoptotic proteins like BCL-2 or MCL-1 is frequently observed in hematologic and solid tumors, facilitating chemoresistance and cell survival (Roberts et al., 2016). Conversely, excessive activation of apoptotic pathways contributes to the loss of post-mitotic cells in neurodegenerative diseases and myocardial infarction. Pharmacological intervention targeting these proteins has seen significant success, most notably with the development of BH3 mimetics like venetoclax, which selectively inhibits BCL-2 to induce apoptosis in malignant cells. Ongoing research continues to explore the therapeutic potential of modulating these pathways to either eliminate cancer cells or preserve healthy tissue in degenerative conditions (Silke & Vucic, 2014).

Other names

Programmed cell death regulatorsApoptotic regulatorsBcl-2 family proteinsCaspasesInhibitor of Apoptosis Proteins (IAPs)

Inhibition of anti-apoptotic proteins (e.g., BCL-2, MCL-1) to restore apoptotic sensitivity; activation of pro-apoptotic signaling through death receptor agonism; or inhibition of executioner caspases to prevent cell loss.